These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26707313)

  • 21. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution.
    Zekry A; Whiting P; Crawford DH; Angus PW; Jeffrey GP; Padbury RT; Gane EJ; McCaughan GW;
    Liver Transpl; 2003 Apr; 9(4):339-47. PubMed ID: 12682883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients.
    Núñez-Torres R; Macías J; Mancebo M; Frías M; Dolci G; Téllez F; Merino D; Merchante N; Gómez-Mateos J; Guaraldi G; Rivero-Juárez A; Pineda JA; Real LM;
    PLoS One; 2016; 11(12):e0168265. PubMed ID: 27973562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PNPLA3 rs738409 polymorphism is associated with liver fibrosis progression in patients with chronic hepatitis C: A repeated measures study.
    Jiménez-Sousa MÁ; Gómez-Moreno AZ; Pineda-Tenor D; Sánchez-Ruano JJ; Fernández-Rodríguez A; Artaza-Varasa T; Gómez-Sanz A; Martín-Vicente M; Vázquez-Morón S; Resino S
    J Clin Virol; 2018 Jun; 103():71-74. PubMed ID: 29674183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
    Prieto M; Berenguer M; Rayón JM; Córdoba J; Argüello L; Carrasco D; García-Herola A; Olaso V; De Juan M; Gobernado M; Mir J; Berenguer J
    Hepatology; 1999 Jan; 29(1):250-6. PubMed ID: 9862874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Synergistic Effect of TNFα -308 G/A and TGFβ1 -509 C/T Polymorphisms on Hepatic Fibrosis Progression in Hepatitis C Virus Genotype 4 Patients.
    Bader El Din NG; Farouk S; El-Shenawy R; Elhady MM; Ibrahim MK; Dawood RM; Salem AM; El Awady MK
    Viral Immunol; 2017 Mar; 30(2):127-135. PubMed ID: 28151059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection.
    Ali M; Yopp A; Gopal P; Beg MS; Zhu H; Lee W; Singal AG
    Clin Gastroenterol Hepatol; 2016 Feb; 14(2):295-300. PubMed ID: 26305067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. rs8099917 and viral genotyping as indications for living donor liver transplantation for hepatitis C: a case report.
    Yoshida Y; Ikegami T; Yoshizumi T; Toshima T; Yamashita YI; Yoshiya S; Shirabe K; Maehara Y
    Transplant Proc; 2014 Sep; 46(7):2426-9. PubMed ID: 25150603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PNPLA3 and RNF7 Gene Variants are Associated with the Risk of Developing Liver Fibrosis and Cirrhosis in an Eastern European Population.
    Kupcinskas J; Valantiene I; Varkalaitė G; Steponaitiene R; Skieceviciene J; Sumskiene J; Petrenkiene V; Kondrackiene J; Kiudelis G; Lammert F; Kupcinskas L
    J Gastrointestin Liver Dis; 2017 Mar; 26(1):37-43. PubMed ID: 28338112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low Molecular Mass Polypeptide 7 Single Nucleotide Polymorphism is Associated with the Progression of Liver Fibrosis in Patients Infected with Hepatitis C Virus Genotype 4.
    El Awady MK; Omran MH; Ibrahim MK; Moustafa AM; Dawood RM; Bader El Din NG; Elsharkawy A; Abdel Aziz MS; El Shenawy R; El Abd YS; Abdel Aziz AO
    Clin Lab; 2016; 62(3):381-7. PubMed ID: 27156327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients.
    O'Leary JG; Kaneku H; Jennings L; Susskind BM; Terasaki PI; Klintmalm GB
    Liver Transpl; 2014 Jun; 20(6):655-63. PubMed ID: 24678017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection.
    Moqueet N; Cooper C; Gill J; Hull M; Platt RW; Klein MB;
    J Infect Dis; 2016 Jul; 214(1):80-6. PubMed ID: 26984148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.
    Song AT; Sobesky R; Vinaixa C; Dumortier J; Radenne S; Durand F; Calmus Y; Rousseau G; Latournerie M; Feray C; Delvart V; Roche B; Haim-Boukobza S; Roque-Afonso AM; Castaing D; Abdala E; D'Albuquerque LA; Duclos-Vallée JC; Berenguer M; Samuel D
    World J Gastroenterol; 2016 May; 22(18):4547-58. PubMed ID: 27182164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of common risk factors of fibrosis progression in chronic hepatitis C.
    Rüeger S; Bochud PY; Dufour JF; Müllhaupt B; Semela D; Heim MH; Moradpour D; Cerny A; Malinverni R; Booth DR; Suppiah V; George J; Argiro L; Halfon P; Bourlière M; Talal AH; Jacobson IM; Patin E; Nalpas B; Poynard T; Pol S; Abel L; Kutalik Z; Negro F
    Gut; 2015 Oct; 64(10):1605-15. PubMed ID: 25214320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrent hepatitis C virus infection and outcome after living-donor liver transplant.
    Satapathy SK; Fiel MI; Vanatta JM; Del Rio Martin J; Schiano TD
    Exp Clin Transplant; 2013 Dec; 11(6):522-9. PubMed ID: 23901801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-28B polymorphism in hepatitis C and liver transplantation.
    Duarte-Rojo A; Deneke MG; Charlton MR
    Liver Transpl; 2013 Jan; 19(1):49-58. PubMed ID: 23008132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrosis progression and the pros and cons of antiviral therapy for hepatitis C virus recurrence after liver transplantation: a review.
    De Martin E; Senzolo M; Gambato M; Germani G; Vitale A; Russo FR; Burra P
    Transplant Proc; 2010; 42(6):2223-5. PubMed ID: 20692449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 7-gene signature of the recipient predicts the progression of fibrosis after liver transplantation for hepatitis C virus infection.
    do O NT; Eurich D; Schmitz P; Schmeding M; Heidenhain C; Bahra M; Trautwein C; Neuhaus P; Neumann UP; Wasmuth HE
    Liver Transpl; 2012 Mar; 18(3):298-304. PubMed ID: 22139994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation.
    Terrault NA; Shiffman ML; Lok AS; Saab S; Tong L; Brown RS; Everson GT; Reddy KR; Fair JH; Kulik LM; Pruett TL; Seeff LB;
    Liver Transpl; 2007 Jan; 13(1):122-9. PubMed ID: 17192908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
    Konishi H; Motomura T; Matsumoto Y; Harimoto N; Ikegami T; Yoshizumi T; Soejima Y; Shirabe K; Fukuhara T; Maehara Y
    J Viral Hepat; 2014 Jun; 21(6):397-404. PubMed ID: 24750545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic variants of STAT-4 affect the development of graft fibrosis after liver transplantation for HCV-induced liver disease.
    Eurich D; Boas-Knoop S; Struecker B; Neuhaus R; Neuhaus P; Bahra M
    Transplantation; 2013 Jan; 95(1):203-8. PubMed ID: 23202532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.